About Lipofabrik
Lipofabrik is a company based in Villeneuve-d'ascq (France) founded in 2013 was acquired by Groupe Elephant Vert in February 2022. Lipofabrik operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Villeneuve-d'ascq, France
- SectorsChemicals & MaterialsHealthcare
- Email••••••••
- Website lipofabrik.com
- Acquired by Groupe Elephant Vert (Feb 2022)
- Latest Funding Round$1.78M (USD), Grant
Apr 2019
- InvestorsEuropean Union
& 1 more
- Acquired byGroupe Elephant Vert
(Feb 2022)
Funding Insights of Lipofabrik
- Total Rounds 2
- Last Round Grant — $1.78M
- First Round $60,054
(Jan 2018)
- Investors Count 1
All 2 funding rounds of Lipofabrik with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2019 | $1.78M | Grant | – | – | |
| Jan 2018 | $60,054 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Lipofabrik
Lipofabrik has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include European Union and Groupe Elephant Vert.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Bio-based solutions are developed and distributed for sustainable agriculture. | 2012 | elephant-vert.com | Rabat, Morocco |
Investor details for Lipofabrik
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Lipofabrik
4 dated milestones of Lipofabrik across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Lipofabrik is founded.
- Funding First funding round of $60K.
- Funding Latest funding round, Grant, of $1.8M.
- Exit Acquired by Groupe Elephant Vert.
Competitors of Lipofabrik
Lipofabrik operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of Lipofabrik
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Lipofabrik
10 companies that operate in the same segment as Lipofabrik (Chemicals Tech), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Microbe-based plant protection products and yield optimization services are provided. | 2013 | Boston, Massachusetts, United States | USD 1.4 B | – | – | |
Plant-based biopesticides are developed for agricultural applications by Terramera. | 2010 | Vancouver, British Columbia, Canada | USD 64.94 M | USD 3.42 M | 16 | |
Conductive nanocoatings are delivered via atomic layer deposition technology. | 2013 | Boulder, Colorado, United States | USD 202.75 M | – | – | |
Developr of bio-based products and natural compounds for biotechnological solutions | 1993 | Zwingenberg, Hesse, Germany | USD 5.38 M | – | – | |
Sustainable bio-based chemicals are manufactured using a proprietary platform. | 2016 | Houston, Texas, United States | USD 686.05 M | – | – | |
Biological insecticides and pesticides are developed from spider peptides. | 2001 | Kalamazoo, Michigan, United States | USD 286.68 M | – | – | |
Nitrogen-fixing microbes for corn crop nutrition are developed and applied. | 2010 | Berkeley, California, United States | USD 618.08 M | – | – | |
Instruments and software for color calibration are developed by Datacolor. | 1970 | Lawrenceville, United States | – | USD 781.59 K | 20 | |
Green acids are produced from microbes via synthetic biology. | 2010 | Emeryville, California, United States | USD 51.77 M | – | – | |
Phytochemicals are developed using microbial fermentation processes. | 2011 | Cambridge, Massachusetts, United States | USD 115.93 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Lipofabrik
Lipofabrik was founded in 2013 and raised its 1st funding round 5 years after it was founded.
Lipofabrik is headquartered in Villeneuve-d'ascq, France. It is registered at Villeneuve-d'ascq, Hauts-de-france, France.
Lipofabrik is focussed on the production, purification, formulation and sales of biological and biodegradable molecules produced through bioprocesses based on renewable resources. Based on the research program developed at Probiogem laboratory, it is currently working on developing 6 different types of lipopeptides including Fengycin, Plipastatin, Iturin, Lichenysin, Mycosubtilin, Surfactin. It claims that these molecules possess physico-chemical properties and biological activities with the applications as emulsifier, surfactant, antimicrobial and plant systemic resistance inducer.
Lipofabrik's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Lipofabrik has 2 investors. Key investors include European Union, and Groupe Elephant Vert.
Yes. Lipofabrik was acquired by Groupe Elephant Vert in February 2022.